The mix of those ideas raised new analytical potentialities, opening an unprecedented subject of refined exploration for a lot of situations, together with hematopoiesis and hematological issues. On this assessment, the final ideas and progress achieved within the growth of recent analytical approaches for exploring high-dimensional knowledge units on the single-cell stage will likely be described as they appeared over the previous few years. A bigger and extra sensible half will element the assorted steps that should be mastered, each in knowledge acquisition and within the preanalytical test of information recordsdata.
Lastly, a step-by-step rationalization of the answer in growth to mix the Bioconductor clustering algorithm FlowSOM and the favored and broadly used software program Kaluza® (Beckman Coulter) will likely be introduced. The goal of this assessment was to level out that the day when these progresses will attain routine hematology laboratories doesn’t appear so far-off.
Detection of Immune Checkpoint Receptors – A Present Problem in Scientific Movement Cytometry
Immunological remedy ideas are more and more figuring out fashionable drugs. They’re used to deal with ailments of the immune system, for tumors, but additionally for infections, neurological ailments, and plenty of others. Most of those therapies base on antibodies, however small molecules, soluble receptors or cells and modified cells are additionally used. The event of immune checkpoint inhibitors is amazingly quick. T-cell directed antibody therapies in opposition to PD-1 or CTLA-Four are already firmly established within the clinic. Additional targets are continually being added and it’s changing into more and more clear that their expression just isn’t solely related on T cells. Moreover, we don’t but have any expertise with the long-term systemic results of the therapy.
Movement cytometry can be utilized for prognosis, monitoring, and detection of unwanted effects. On this assessment, we concentrate on checkpoint molecules as goal molecules and purposeful markers of cells of the innate and purchased immune system. Nonetheless, for many of the attention-grabbing and doubtlessly related parameters, there are nonetheless no take a look at kits appropriate for routine use. Right here we give an outline of the detection of checkpoint molecules on immune cells within the peripheral blood and present examples of a potential design of antibody panels.
The design of focused nanomedicines requires intracellular space- and time-resolved knowledge of nanoparticle distribution following uptake. Present strategies to review intracellular trafficking, akin to dynamic colocalization by fluorescence microscopy in stay cells, are normally low throughput and require in depth evaluation of enormous datasets to quantify colocalization in a number of particular person cells. Right here a way primarily based on move cytometry to simply detect and characterize the organelles through which nanoparticles are internalized and trafficked over time is proposed.
Standard cell fractionation strategies are mixed with immunostaining and high-sensitivity organelle move cytometry to get space-resolved knowledge of nanoparticle intracellular distribution. By extracting the organelles at completely different instances, time-resolved knowledge of nanoparticle intracellular trafficking are obtained. The strategy is validated by figuring out how nanoparticle measurement impacts the kinetics of arrival to the lysosomes. The outcomes reveal that this methodology permits high-throughput evaluation of nanoparticle uptake and intracellular trafficking by cells, subsequently it may be used to find out how nanoparticle design impacts their intracellular habits.
Movement cytometry knowledge mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells
The phenotype of infused cells is a serious determinant of Adoptive T-cell remedy (ACT) efficacy. But, the problem in deciphering multiparametric cytometry knowledge restricted the high quality characterization of mobile merchandise. To permit the evaluation of dynamic and sophisticated move cytometry samples we developed cytoChain, a novel dataset mining instrument and a brand new analytical workflow. CytoChain was challenged to match state-of-the-art and revolutionary tradition situations to generate stem-like reminiscence cells (TSCM ) appropriate for ACT. Noticeably, the mix of IL-7/15 and super-oxides scavenging sustained the emergence of a beforehand un-identified non-exhausted Match-TSCM signature, ignored by handbook gating and endowed with superior growth potential.
CytoChain proficiently traced again this inhabitants in unbiased datasets, and in T-cell receptor engineered lymphocytes. cytoChain flexibility and performance had been then additional validated on a broadcast dataset from circulating T cells in COVID-19 sufferers. Collectively, our outcomes assist using cytoChain to establish novel, functionally essential immunophenotypes for ACT and sufferers immunomonitoring. This text is protected by copyright. All rights reserved. Environment friendly doubled haploid (DH) plant manufacturing is of nice curiosity within the plant breeding business and analysis as a result of homozygous traces are obtained inside a single era shortening the breeding cycle considerably.
 SDCCAG3 Antibody, Biotin conjugated |
|||
| 1-CSB-PA020897LD01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDCCAG3. Recognizes SDCCAG3 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
 SDCCAG3 Polyclonal Antibody, HRP Conjugated |
|||
| A69692 | EpiGentek |
|
|
 SDCCAG3 Polyclonal Antibody, FITC Conjugated |
|||
| A69693 | EpiGentek |
|
|
 SDCCAG3 Polyclonal Antibody, Biotin Conjugated |
|||
| A69694 | EpiGentek |
|
|
 SDCCAG8 Antibody |
|||
| 43294-100ul | SAB | 100ul | EUR 302.4 |
 SDCCAG8 antibody |
|||
| 70R-20131 | Fitzgerald | 50 ul | EUR 522 |
|
Description: Rabbit polyclonal SDCCAG8 antibody |
|||
SDCCAG8 antibody |
|||
| 70R-4002 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal SDCCAG8 antibody raised against the N terminal of SDCCAG8 |
|||
SDCCAG8 antibody |
|||
| 70R-4128 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal SDCCAG8 antibody raised against the middle region of SDCCAG8 |
|||
SDCCAG8 Antibody |
|||
| ABD8846 | Lifescience Market | 100 ug | EUR 525.6 |
SDCCAG8 Antibody |
|||
| DF8846 | Affbiotech | 200ul | EUR 420 |
SDCCAG8 Antibody |
|||
| 1-CSB-PA020899GA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDCCAG8. Recognizes SDCCAG8 from Human, Mouse, Rat, Zebrafish. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF |
|||
SDCCAG8 Antibody |
|||
| 1-CSB-PA006722 | Cusabio |
|
|
|
Description: A polyclonal antibody against SDCCAG8. Recognizes SDCCAG8 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/20000 |
|||
SDCCAG8 Antibody |
|||
| R36187-100UG | NSJ Bioreagents | 100 ug | EUR 339.15 |
|
Description: Additional name(s) for this target protein: Serologically defined colon cancer antigen 8 |
|||
 anti- SDCCAG8 antibody |
|||
| FNab07666 | FN Test | 100µg | EUR 606.3 |
|
Description: Antibody raised against SDCCAG8 |
|||
) Polyclonal SDCCAG8 Antibody (Internal) |
|||
| APG01216G | Leading Biology | 0.05mg | EUR 580.8 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human SDCCAG8 (Internal). This antibody is tested and proven to work in the following applications: |
|||
) Polyclonal SDCCAG8 Antibody (aa469-483) |
|||
| APG01240G | Leading Biology | 0.05mg | EUR 580.8 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human SDCCAG8 (aa469-483). This antibody is tested and proven to work in the following applications: |
|||
) Polyclonal SDCCAG8 Antibody (internal region) |
|||
| APG00810G | Leading Biology | 0.1mg | EUR 580.8 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human SDCCAG8 (internal region). This antibody is tested and proven to work in the following applications: |
|||
 SDCCAG8 siRNA |
|||
| 20-abx932704 | Abbexa |
|
|
SDCCAG8 siRNA |
|||
| 20-abx932705 | Abbexa |
|
|
 SDCCAG8 Peptide |
|||
| 43-022P | ProSci | 0.1 mg | EUR 405.6 |
|
Description: SDCCAG8 Peptide |
|||
SDCCAG8 Peptide |
|||
| 43-023P | ProSci | 0.1 mg | EUR 405.6 |
|
Description: SDCCAG8 Peptide |
|||
 Antibody) Serologically Defined Colon Cancer Antigen 8 (SDCCAG8) Antibody |
|||
| abx237666-100ug | Abbexa | 100 ug | EUR 577.2 |
Serologically Defined Colon Cancer Antigen 8 (SDCCAG8) Antibody |
|||
| 20-abx121727 | Abbexa |
|
|
Serologically Defined Colon Cancer Antigen 8 (SDCCAG8) Antibody |
|||
| 20-abx325189 | Abbexa |
|
|
Serologically Defined Colon Cancer Antigen 8 (SDCCAG8) Antibody |
|||
| 20-abx115458 | Abbexa |
|
|
Serologically Defined Colon Cancer Antigen 8 (SDCCAG8) Antibody |
|||
| abx029545-400ul | Abbexa | 400 ul | EUR 627.6 |
Serologically Defined Colon Cancer Antigen 8 (SDCCAG8) Antibody |
|||
| abx029545-80l | Abbexa | 80 µl | EUR 343.2 |
Serologically Defined Colon Cancer Antigen 8 (SDCCAG8) Antibody |
|||
| abx432203-200ul | Abbexa | 200 ul | EUR 460.8 |
Serologically Defined Colon Cancer Antigen 8 (SDCCAG8) Antibody |
|||
| abx432204-200ul | Abbexa | 200 ul | EUR 343.2 |
 Antibody (internal region)) Polyclonal SDCCAG8 (aa469-483) Antibody (internal region) |
|||
| APG00811G | Leading Biology | 0.1mg | EUR 580.8 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human SDCCAG8 (aa469-483) (internal region). This antibody is tested and proven to work in the following applications: |
|||
 SDCCAG8 cloning plasmid |
|||
| CSB-CL020899HU-10ug | Cusabio | 10ug | EUR 495.6 |
|
Description: A cloning plasmid for the SDCCAG8 gene. |
|||
 SDCCAG8 Blocking Peptide |
|||
| 33R-3716 | Fitzgerald | 100 ug | EUR 216 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SDCCAG8 antibody, catalog no. 70R-4002 |
|||
SDCCAG8 Blocking Peptide |
|||
| 33R-4109 | Fitzgerald | 100 ug | EUR 216 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SDCCAG8 antibody, catalog no. 70R-4128 |
|||
SDCCAG8 Blocking Peptide |
|||
| DF8846-BP | Affbiotech | 1mg | EUR 234 |
SDCCAG8 Blocking Peptide |
|||
| 20-abx161437 | Abbexa |
|
|
 SDCCAG8 ELISA KIT|Human |
|||
| EF002773 | Lifescience Market | 96 Tests | EUR 826.8 |
 Human SDCCAG8 ELISA KIT |
|||
| ELI-29645h | Lifescience Market | 96 Tests | EUR 988.8 |
 Mouse Sdccag8 ELISA KIT |
|||
| ELI-13424m | Lifescience Market | 96 Tests | EUR 1038 |
 Human SDCCAG8 shRNA Plasmid |
|||
| 20-abx957365 | Abbexa |
|
|
 Mouse SDCCAG8 shRNA Plasmid |
|||
| 20-abx978693 | Abbexa |
|
|
) SDCCAG8 Recombinant Protein (Rat) |
|||
| RP227798 | ABM | 100 ug | Ask for price |
 (pORF)) Sdccag8 ORF Vector (Rat) (pORF) |
|||
| ORF075934 | ABM | 1.0 ug DNA | EUR 607.2 |
) SDCCAG8 Recombinant Protein (Mouse) |
|||
| RP170432 | ABM | 100 ug | Ask for price |
) SDCCAG8 Recombinant Protein (Human) |
|||
| RP096258 | ABM | 100 ug | Ask for price |
 (pORF)) SDCCAG8 ORF Vector (Human) (pORF) |
|||
| ORF032087 | ABM | 1.0 ug DNA | EUR 486 |
 (pORF)) Sdccag8 ORF Vector (Mouse) (pORF) |
|||
| ORF056812 | ABM | 1.0 ug DNA | EUR 607.2 |
 Sdccag8 3'UTR GFP Stable Cell Line |
|||
| TU168462 | ABM | 1.0 ml | Ask for price |
 SDCCAG8 3'UTR GFP Stable Cell Line |
|||
| TU072786 | ABM | 1.0 ml | EUR 1672.8 |
Sdccag8 3'UTR GFP Stable Cell Line |
|||
| TU270027 | ABM | 1.0 ml | Ask for price |
) Sdccag8 sgRNA CRISPR Lentivector set (Rat) |
|||
| K7466701 | ABM | 3 x 1.0 ug | EUR 406.8 |
 (pPM-C-HA)) SDCCAG8 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV303736 | ABM | 500 ng | EUR 1399.2 |
) Sdccag8 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3434501 | ABM | 3 x 1.0 ug | EUR 406.8 |
) SDCCAG8 sgRNA CRISPR Lentivector set (Human) |
|||
| K2108401 | ABM | 3 x 1.0 ug | EUR 406.8 |
 (pPB-C-His)) SDCCAG8 Protein Vector (Rat) (pPB-C-His) |
|||
| PV303734 | ABM | 500 ng | EUR 1399.2 |
 (pPB-N-His)) SDCCAG8 Protein Vector (Rat) (pPB-N-His) |
|||
| PV303735 | ABM | 500 ng | EUR 1399.2 |
 (pPM-C-His)) SDCCAG8 Protein Vector (Rat) (pPM-C-His) |
|||
| PV303737 | ABM | 500 ng | EUR 1399.2 |
 (pPM-C-HA)) SDCCAG8 Protein Vector (Human) (pPM-C-HA) |
|||
| PV128348 | ABM | 500 ng | EUR 662.4 |
 (pPM-C-HA)) SDCCAG8 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV227248 | ABM | 500 ng | EUR 1278 |
 (pPB-C-His)) SDCCAG8 Protein Vector (Human) (pPB-C-His) |
|||
| PV128346 | ABM | 500 ng | EUR 662.4 |
 (pPB-N-His)) SDCCAG8 Protein Vector (Human) (pPB-N-His) |
|||
| PV128347 | ABM | 500 ng | EUR 662.4 |
 (pPM-C-His)) SDCCAG8 Protein Vector (Human) (pPM-C-His) |
|||
| PV128349 | ABM | 500 ng | EUR 662.4 |
 (pPB-C-His)) SDCCAG8 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV227246 | ABM | 500 ng | EUR 1278 |
 (pPB-N-His)) SDCCAG8 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV227247 | ABM | 500 ng | EUR 1278 |
 (pPM-C-His)) SDCCAG8 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV227249 | ABM | 500 ng | EUR 1278 |
 Sdccag8 3'UTR Luciferase Stable Cell Line |
|||
| TU118462 | ABM | 1.0 ml | Ask for price |
 SDCCAG8 3'UTR Luciferase Stable Cell Line |
|||
| TU022786 | ABM | 1.0 ml | EUR 1672.8 |
Sdccag8 3'UTR Luciferase Stable Cell Line |
|||
| TU220027 | ABM | 1.0 ml | Ask for price |
 (Target 1)) Sdccag8 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K7466702 | ABM | 1.0 ug DNA | EUR 184.8 |
 (Target 2)) Sdccag8 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K7466703 | ABM | 1.0 ug DNA | EUR 184.8 |
 (Target 3)) Sdccag8 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K7466704 | ABM | 1.0 ug DNA | EUR 184.8 |
 (Target 1)) Sdccag8 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K3434502 | ABM | 1.0 ug DNA | EUR 184.8 |
 (Target 2)) Sdccag8 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K3434503 | ABM | 1.0 ug DNA | EUR 184.8 |
 (Target 3)) Sdccag8 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K3434504 | ABM | 1.0 ug DNA | EUR 184.8 |
 (Target 1)) SDCCAG8 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K2108402 | ABM | 1.0 ug DNA | EUR 184.8 |
 (Target 2)) SDCCAG8 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K2108403 | ABM | 1.0 ug DNA | EUR 184.8 |
 (Target 3)) SDCCAG8 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K2108404 | ABM | 1.0 ug DNA | EUR 184.8 |
 SDCCAG10 antibody |
|||
| 70R-20129 | Fitzgerald | 50 ul | EUR 522 |
|
Description: Rabbit polyclonal SDCCAG10 antibody |
|||
 SDCCAG1 Antibody |
|||
| abx237663-100ug | Abbexa | 100 ug | EUR 610.8 |
 SDCCAG3 antibody |
|||
| 23110-100ul | SAB | 100ul | EUR 468 |
SDCCAG3 antibody |
|||
| 70R-12961 | Fitzgerald | 100 ul | EUR 548.4 |
|
Description: Affinity purified Rabbit polyclonal SDCCAG3 antibody |
|||
 SDCCAG1 antibody |
|||
| 70R-20128 | Fitzgerald | 50 ul | EUR 522 |
|
Description: Rabbit polyclonal SDCCAG1 antibody |
|||
SDCCAG3 antibody |
|||
| 70R-20130 | Fitzgerald | 50 ul | EUR 522 |
|
Description: Rabbit polyclonal SDCCAG3 antibody |
|||
 SDCCAG3 Antibody |
|||
| 35706-100ul | SAB | 100ul | EUR 302.4 |
SDCCAG3 Antibody |
|||
| 1-CSB-PA037904 | Cusabio |
|
|
|
Description: A polyclonal antibody against SDCCAG3. Recognizes SDCCAG3 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:50-1:200 |
|||
SDCCAG3 Antibody |
|||
| 1-CSB-PA265061 | Cusabio |
|
|
|
Description: A polyclonal antibody against SDCCAG3. Recognizes SDCCAG3 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:2000-1:5000, WB:1:500-1:2000 |
|||
SDCCAG3 Antibody |
|||
| DF13676 | Affbiotech | 100ul | EUR 420 |
SDCCAG3 Antibody |
|||
| 1-CSB-PA020897GA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDCCAG3. Recognizes SDCCAG3 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC |
|||
SDCCAG3 Antibody |
|||
| 1-CSB-PA020897LA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDCCAG3. Recognizes SDCCAG3 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:200-1:500, IF:1:50-1:200 |
|||
 anti- SDCCAG10 antibody |
|||
| FNab07664 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against SDCCAG10 |
|||
 anti- SDCCAG1 antibody |
|||
| FNab07663 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against SDCCAG1 |
|||
 anti- SDCCAG3 antibody |
|||
| FNab07665 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against SDCCAG3 |
|||
 (CMV) (pLenti-GIII-CMV)) SDCCAG8 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV637435 | ABM | 1.0 ug DNA | EUR 1626 |
 (UbC) (pLenti-GIII-UbC)) SDCCAG8 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV637439 | ABM | 1.0 ug DNA | EUR 1626 |
 (EF1a) (pLenti-GIII-EF1a)) SDCCAG8 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV637440 | ABM | 1.0 ug DNA | EUR 1626 |
 Goat Anti-Human IgG Secondary Antibody Cy3 Conjugated |
|||
| L30211 | SAB | 1.0 ml | EUR 134.4 |
 Goat Anti-Mouse IgG Secondary Antibody Cy3 Conjugated |
|||
| L30311 | SAB | 1.0 ml | EUR 134.4 |
 Goat Anti-Rabbit IgG Secondary Antibody Cy3 Conjugated |
|||
| L30111 | SAB | 1.0 ml | EUR 134.4 |
 ELISA Kit) Human Serologically Defined Colon Cancer Antigen 8 (SDCCAG8) ELISA Kit |
|||
| abx383072-96tests | Abbexa | 96 tests | EUR 1093.2 |
) Sdccag8 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K7466705 | ABM | 3 x 1.0 ug | EUR 451.2 |
) Sdccag8 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K3434505 | ABM | 3 x 1.0 ug | EUR 451.2 |
) SDCCAG8 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K2108405 | ABM | 3 x 1.0 ug | EUR 451.2 |
 SDC4 Conjugated Antibody |
|||
| C38308 | SAB | 100ul | EUR 476.4 |
 SDC3 Conjugated Antibody |
|||
| C40231 | SAB | 100ul | EUR 476.4 |
 SDC1 Conjugated Antibody |
|||
| C32248 | SAB | 100ul | EUR 476.4 |
 SDC2 Conjugated Antibody |
|||
| C35086 | SAB | 100ul | EUR 476.4 |
 Cy3 Conjugated Avidin |
|||
| BA1037 | BosterBio | 0.5ml | EUR 194.4 |
 SDCCAG3 Polyclonal Antibody |
|||
| A69691 | EpiGentek |
|
|
 (Target 1)) Sdccag8 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K7466706 | ABM | 1.0 ug DNA | EUR 200.4 |
 (Target 2)) Sdccag8 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K7466707 | ABM | 1.0 ug DNA | EUR 200.4 |
 (Target 3)) Sdccag8 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K7466708 | ABM | 1.0 ug DNA | EUR 200.4 |
 secondary antibody) Cy3 Conjugated Goat Anti-Mouse IgG (H+L) secondary antibody |
|||
| BA1031 | BosterBio | 0.5ml | EUR 218.4 |
 secondary antibody) Cy3 Conjugated Goat Anti-Rabbit IgG (H+L) secondary antibody |
|||
| BA1032 | BosterBio | 0.5ml | EUR 218.4 |
 secondary antibody) Cy3 Conjugated Rabbit Anti-Goat IgG (H+L) secondary antibody |
|||
| BA1034 | BosterBio | 0.5ml | EUR 218.4 |
 (Target 1)) Sdccag8 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
| K3434506 | ABM | 1.0 ug DNA | EUR 200.4 |
 (Target 2)) Sdccag8 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
| K3434507 | ABM | 1.0 ug DNA | EUR 200.4 |
 (Target 3)) Sdccag8 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
| K3434508 | ABM | 1.0 ug DNA | EUR 200.4 |
 (Target 1)) SDCCAG8 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K2108406 | ABM | 1.0 ug DNA | EUR 200.4 |
 (Target 2)) SDCCAG8 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K2108407 | ABM | 1.0 ug DNA | EUR 200.4 |
 (Target 3)) SDCCAG8 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K2108408 | ABM | 1.0 ug DNA | EUR 200.4 |
 secondary antibody) Cy3 Conjugated Rabbit Anti-Human IgG (H+L) secondary antibody |
|||
| BA1035 | BosterBio | 0.5ml | EUR 218.4 |
 SDC1 Antibody, HRP conjugated |
|||
| 1-CSB-PA020888HB01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDC1. Recognizes SDC1 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
 SDC4 Antibody, HRP conjugated |
|||
| 1-CSB-PA327046HB01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDC4. Recognizes SDC4 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
 (CMV) (pLenti-GIII-CMV-C-term-HA)) SDCCAG8 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV637436 | ABM | 1.0 ug DNA | EUR 1626 |
 SDC1 Antibody, FITC conjugated |
|||
| 1-CSB-PA020888HC01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDC1. Recognizes SDC1 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
 SDC4 Antibody, FITC conjugated |
|||
| 1-CSB-PA327046HC01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDC4. Recognizes SDC4 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
 (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)) SDCCAG8 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV637437 | ABM | 1.0 ug DNA | EUR 1695.6 |
 (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)) SDCCAG8 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV637438 | ABM | 1.0 ug DNA | EUR 1695.6 |
 SDCBP Conjugated Antibody |
|||
| C42808 | SAB | 100ul | EUR 476.4 |
SDCBP Conjugated Antibody |
|||
| C32800 | SAB | 100ul | EUR 476.4 |
 SDCG1 Conjugated Antibody |
|||
| C33600 | SAB | 100ul | EUR 476.4 |
 SDC1 Antibody, Biotin conjugated |
|||
| 1-CSB-PA020888HD01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDC1. Recognizes SDC1 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
 SDC4 Antibody, Biotin conjugated |
|||
| 1-CSB-PA327046HD01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDC4. Recognizes SDC4 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
 SDC1 Polyclonal Conjugated Antibody |
|||
| C41975 | SAB | 100ul | EUR 476.4 |
 SDCBP Antibody, HRP conjugated |
|||
| 1-CSB-PA020893LB01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDCBP. Recognizes SDCBP from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
 SDCBP2 Antibody, HRP conjugated |
|||
| 1-CSB-PA872430LB01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDCBP2. Recognizes SDCBP2 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
 SDCBP Antibody, FITC conjugated |
|||
| 1-CSB-PA020893LC01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDCBP. Recognizes SDCBP from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
 Antibody) CWC27 Spliceosome Associated Protein Homolog (SDCCAG10) Antibody |
|||
| abx237664-100ug | Abbexa | 100 ug | EUR 610.8 |
 SDCBP2 Antibody, FITC conjugated |
|||
| 1-CSB-PA872430LC01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDCBP2. Recognizes SDCBP2 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
 SDCBP Antibody, Biotin conjugated |
|||
| 1-CSB-PA020893LD01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDCBP. Recognizes SDCBP from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
 Antibody) Serologically Defined Colon Cancer Antigen 3 (SDCCAG3) Antibody |
|||
| abx237665-100ug | Abbexa | 100 ug | EUR 610.8 |
 Antibody) Serologically defined colon cancer antigen 3 (SDCCAG3) Antibody |
|||
| 20-abx213359 | Abbexa |
|
|
Serologically defined colon cancer antigen 3 (SDCCAG3) Antibody |
|||
| 20-abx213492 | Abbexa |
|
|
Serologically Defined Colon Cancer Antigen 3 (SDCCAG3) Antibody |
|||
| 20-abx115457 | Abbexa |
|
|
Serologically defined colon cancer antigen 3 (SDCCAG3) Antibody |
|||
| 20-abx334226 | Abbexa |
|
|
Serologically Defined Colon Cancer Antigen 3 (SDCCAG3) Antibody |
|||
| 20-abx005975 | Abbexa |
|
|
 SDC1 Polyclonal Antibody, HRP Conjugated |
|||
| A56800 | EpiGentek |
|
|
 SDCBP2 Antibody, Biotin conjugated |
|||
| 1-CSB-PA872430LD01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against SDCBP2. Recognizes SDCBP2 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
 Antibody (HRP)) Serologically defined colon cancer antigen 3 (SDCCAG3) Antibody (HRP) |
|||
| 20-abx337646 | Abbexa |
|
|
 Antibody (FITC)) Serologically defined colon cancer antigen 3 (SDCCAG3) Antibody (FITC) |
|||
| 20-abx337647 | Abbexa |
|
|
 SDC1 Polyclonal Antibody, FITC Conjugated |
|||
| A56801 | EpiGentek |
|
|
 Cy3 Conjugated anti-Rat IgG SABC Kit |
|||
| SA1079 | BosterBio | 1 kit | EUR 426 |
 Cy3 Conjugated anti-Goat IgG SABC Kit |
|||
| SA1076 | BosterBio | 1 kit | EUR 426 |
 Antibody (Biotin)) Serologically defined colon cancer antigen 3 (SDCCAG3) Antibody (Biotin) |
|||
| 20-abx337648 | Abbexa |
|
|
 Cy3 Conjugated anti-Mouse IgG SABC Kit |
|||
| SA1072 | BosterBio | 1 kit | EUR 426 |
 Cy3 Conjugated anti-Mouse IgM SABC Kit |
|||
| SA1073 | BosterBio | 1 kit | EUR 450 |
 Cy3 Conjugated anti-Human IgG SABC Kit |
|||
| SA1078 | BosterBio | 1 kit | EUR 426 |
 SDC1 Polyclonal Antibody, Biotin Conjugated |
|||
| A56802 | EpiGentek |
|
|
 SDCBP Conjugated Monoclonal Antibody |
|||
| C27105 | SAB | 100ul | EUR 476.4 |
 Cy3 Conjugated anti-Rabbit IgG SABC Kit |
|||
| SA1074 | BosterBio | 1 kit | EUR 426 |
 SDCBP2 Polyclonal Antibody, HRP Conjugated |
|||
| A60821 | EpiGentek |
|
|
 SDCBP2 Polyclonal Antibody, FITC Conjugated |
|||
| A60820 | EpiGentek |
|
|
 SDCBP2 Polyclonal Antibody, Biotin Conjugated |
|||
| A60819 | EpiGentek |
|
|
 CS Conjugated Antibody |
|||
| C43035 | SAB | 100ul | EUR 476.4 |
 KL Conjugated Antibody |
|||
| C43404 | SAB | 100ul | EUR 476.4 |
 XK Conjugated Antibody |
|||
| C43438 | SAB | 100ul | EUR 476.4 |
 Rb Conjugated Antibody |
|||
| C48804 | SAB | 100ul | EUR 476.4 |
 C3 Conjugated Antibody |
|||
| C49413 | SAB | 100ul | EUR 476.4 |
DH protocol growth is usually a time- and resource-consuming course of resulting from quite a few components affecting its success and effectivity. Right here we current ideas and examples about how essential success components might be recognized all through a DH protocol and an early microspore response monitored by easy impedance move cytometry (IFC) measurements, which can assist to optimize every step of an androgenesis-based DH protocol.